11:32 AM
 | 
Sep 28, 2018
 |  BioCentury  |  Emerging Company Profile

Stopping chain swapping

How Elstar’s multispecific antibody platform can increase product yield

By controlling how antibody chains pair, Elstar Therapeutics Inc.’s platform can produce multispecific antibodies at yields comparable to methods for manufacturing monospecific antibodies.

The company develops multispecific antibodies with up to four functional domains that bind tumor cells or modulate immune cells. The functional domains include single-chain variable fragments (scFvs), ligands, cytokines, cytokine traps and enzymes.

Compared with monospecific antibodies, conventional methods for making bi- and multispecific antibodies have lower yields because random combination of the chains and functional domains results in unwanted molecules. Elstar CEO Steve Arkinstall said this random pairing of chains, also called chain swapping, limits yields for those conventional methods to 12.5%. “If you think of a bispecific antibody, it’s basically got four chains: two heavy chains and two light chains. If you express all those four chains in a manufacturing cell line like a CHO cell, you...

Read the full 687 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >